Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 2:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 815 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Liver Disease Clear all
Completed Phase 3 Interventional Results available

Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C

NCT01448044
View directory record Official record
Conditions
Hepatitis C
Interventions
BMS-790052 (NS5A Replication Complex Inhibitor), Placebo matching BMS-790052, Pegylated-interferon alfa 2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
San Clemente, California • Worcester, Massachusetts • Providence, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 6, 2026, 2:12 PM EDT
Completed No phase listed Observational

The Physiology of Fatigue in Patients With Chronic Liver Disease

NCT01867385
View directory record Official record
Conditions
Liver Disease
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 23, 2018 · Synced Oct 6, 2026, 2:12 PM EDT
Completed Phase 1Phase 2 Interventional

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency

NCT04722887
View directory record Official record
Conditions
Alpha1-Antitrypsin Deficiency
Interventions
Alpha-1 15%, Liquid Alpha1-Proteinase Inhibitor (Human)
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
Los Angeles, California • Gainesville, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 6, 2026, 2:12 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation

NCT00065507
View directory record Official record
Conditions
Hepatitis B
Interventions
Entecavir (ETV), Adefovir (ADV)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
16
States / cities
San Diego, California • San Francisco, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 6, 2026, 2:12 PM EDT
Completed Phase 4 Interventional Results available

Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease

NCT00028093
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Peginterferon alfa-2a with Ribavirin, Peginterferon alfa-2a
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Oct 6, 2026, 2:12 PM EDT
Terminated Phase 4 Interventional Results available

Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy

NCT05717400
View directory record Official record
Conditions
Liver Cancer
Interventions
Bevacizumab, Atezolizumab, Sofosbuvir, Velpatasvir, Voxilaprevir, Ribavirin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Oct 6, 2026, 2:12 PM EDT
Completed Phase 2 Interventional

A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)

NCT00008463
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Ribavirin, Interferon alfa-2a, Peginterferon alfa-2a
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
24
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 6, 2026, 2:12 PM EDT
Completed Not applicable Interventional

19Gauge Fine Needle Biopsy (FNB) Versus 22Gauge FNB for Endoscopic Ultrasound Guided Liver Biopsy (EUS-LB)

NCT04806607
View directory record Official record
Conditions
Chronic Liver Disease
Interventions
19G FNB, 22G FNB
Procedure
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years to 89 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 6, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency

NCT03679598
View directory record Official record
Conditions
Alpha-1 Antitrypsin Deficiency (AATD), Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations, Emphysema or COPD
Interventions
Alvelestat (MPH966), Placebo
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 80 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 6, 2026, 2:12 PM EDT
Withdrawn Not applicable Interventional

Use of Omega-3 Fatty Acids (Fish Oil) in Patients With Chronic Hepatitis C Infection

NCT00547716
View directory record Official record
Conditions
Hepatitis C
Interventions
Omega-3 Fatty Acids, Placebo comparator
Dietary Supplement · Drug
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 6, 2026, 2:12 PM EDT
Terminated No phase listed Observational Results available

A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection

NCT02292706
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
Sofosbuvir, Ribavirin, LDV/SOF, SOF/VEL, SOF/VEL/VOX, Other SOF-Based Regimen, Ineligible parent treatment
Drug · Other
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
77
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 57 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 6, 2026, 2:12 PM EDT
Terminated Not applicable Interventional Results available

Ultrasound Method to Measure Fibrosis of the Liver in Children

NCT02086708
View directory record Official record
Conditions
Chronic Liver Disease, Non-Alcoholic Fatty Liver Disease, HCV Coinfection, HBV, Drug-Induced Liver Injury
Interventions
Shear Wave sonoelastography
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
1 Year to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 6, 2026, 2:12 PM EDT
Withdrawn No phase listed Observational

SIMpill Medication Dispensing Device in the Treatment of HCV

NCT01691235
View directory record Official record
Conditions
Chronic Hepatitis C Virus
Interventions
SIMpill device
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Oct 6, 2026, 2:12 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects

NCT01846455
View directory record Official record
Conditions
Hepatic Failure, Hepatic Impairment, Chronic Hepatitis C Infection With Hepatic Coma
Interventions
2.0mg Buprenorphine/0.5mg Naloxone, Promethazine
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
3
States / cities
Hialeah, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Oct 6, 2026, 2:12 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C

NCT01821625
View directory record Official record
Conditions
Thrombocytopenia, Hepatitis C
Interventions
Eltrombopag
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 6, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment

NCT00537407
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Debio 025, Peg-IFNα2a, Ribavirin
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
7
States / cities
La Jolla, California • Gainesville, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 6, 2026, 2:12 PM EDT
Completed Phase 2 Interventional

Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed

NCT00968357
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
SCV-07
Drug
Lead sponsor
SciClone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
16
States / cities
Anaheim, California • Los Angeles, California • Palm Springs, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2012 · Synced Oct 6, 2026, 2:12 PM EDT
Terminated No phase listed Observational

TruGraf Liver Gene Expression Serial Test

NCT06061341
View directory record Official record
Conditions
Autoimmune Liver Disease, Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis
Interventions
TruGraf®
Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 6, 2026, 2:12 PM EDT
Active, not recruiting Phase 3 Interventional

Entecavir to TAF Switch

NCT03489239
View directory record Official record
Conditions
Hepatitis B
Interventions
Tenofovir Alafenamide
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Oct 6, 2026, 2:12 PM EDT
Completed No phase listed Observational Results available

An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1

NCT01508130
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Not listed
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
65
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 53 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 6, 2026, 2:12 PM EDT
Completed Phase 2 Interventional

Gamma Interferon Therapy for Chronic Hepatitis C

NCT00028275
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Gamma Interferon 1b
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 6, 2026, 2:12 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection

NCT00874796
View directory record Official record
Conditions
HCV Infection
Interventions
GS-9450, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
51
States / cities
Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Oct 6, 2026, 2:12 PM EDT
Terminated Not applicable Interventional Results available

Mild Hypothermia and Acute Kidney Injury in Liver Transplantation

NCT03534141
View directory record Official record
Conditions
Cirrhosis, End Stage Liver Disease, Acute Kidney Injury, Liver Transplant; Complications, Chronic Kidney Diseases, Hepatitis c, Hepatitis B, NASH - Nonalcoholic Steatohepatitis, Alcoholic Cirrhosis, Hepatocellular Carcinoma
Interventions
Esophageal cooling/warming device, Mild hypothermia, Normothermia
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
San Francisco, California • Aurora, Colorado • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 6, 2026, 2:12 PM EDT
Completed Phase 1 Interventional Results available

sPIF CLINICAL STUDY PROTOCOL IN AUTOIMMUNE HEPATITIS

NCT02239562
View directory record Official record
Conditions
Autoimmune Hepatitis
Interventions
sPIF, Placebo
Drug
Lead sponsor
Christopher O'Brien, MD
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Miami, Florida • Cherry Hill, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Oct 6, 2026, 2:12 PM EDT